Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vatalinib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Vatalinib | DRUG | - |
Inclusion criteria * Healthy female * Surgically sterile or post-menopausal * At least a weight of 50 kg and have a body mass index (BMI) ≤33.0 * Non-smokers or those who smoke 25 cigarettes or less per day Exclusion criteria * Use of certain prescription and over the counter drugs * Having receive...
Vatalinib is an investigational small molecule kinase inhibitor developed by Novartis AG. It has been studied in a Phase 1 drug-drug interaction trial in healthy sterile or postmenopausal female volunteers. Vatalinib has not been approved by the FDA and remains in clinical development.
Vatalinib is a small molecule kinase inhibitor, belonging to the -nib class of drugs that act on kinase enzymes. Kinase inhibitors work by blocking the activity of specific kinases involved in cellular signaling pathways. The specific molecular target of vatalinib has not been publicly disclosed.
Vatalinib is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker symbol NVS. Novartis is a multinational pharmaceutical company headquartered in Switzerland.
Vatalinib is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not received FDA approval.
Vatalinib has been evaluated in one completed Phase 1 trial, NCT00426452. This drug-drug interaction study examined oral vatalinib at 1250 mg administered under fasting and fed conditions with a proton-pump inhibitor in healthy sterile or postmenopausal female volunteers. The trial enrolled 24 participants and was randomized but uncontrolled.